Skip to main content

Improving health worldwide through new therapeutic options

Our talented team of international experts is committed to developing an innovative and diverse portfolio of breakthrough therapies.

Powered by proprietary cutting-edge long-acting injectable technology, we are redefining standards treatment efficiency and accessibility to enhance the quality of life for patients worldwide.

In our commitment to advancing global health, we collaborate with leading pharmaceutical entities and foundations to introduce groundbreaking therapeutic solutions.

Key figures

1

FDA-approved best-in-class therapy based on our proprietary technology

2

potential first-in-class therapies in Phase 3 clinical trials

140

top-tier experts, all shareholders, steering our company's success

25

nationalities within our team, fostering a diverse and dynamic work environment

Products & R&D pipeline

At the core of our portfolio is a commitment to addressing critical medical challenges, aiming to profoundly impact not only patient lives but also society at large. Our innovative product candidates, rooted in our proprietary BEPO®  long-acting injectable technology, are developed both in-house and in collaboration with leading international pharmaceutical firms and NGOs.

Products on market

UZEDY®

Monthly and every 2 months subcutaneous risperidone for treatment of schizophrenia

Programs in clinical phase 3

mdc-TJK

Once-monthly subcutaneous long-acting injection of olanzapine with a favorable safety profile for the treatment of schizophrenia

mdc-TJK

In partnership with Teva Pharmaceuticals

Indication

Schizophrenia

Molecule

Olanzapine

Status

Clinical Phase 3

Technology

BEPO®

mdc-TJK is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the treatment of schizophrenia. It has the potential to be the first long-acting olanzapine with a favorable safety profile as other LAIs of olanzapine have an FDA black box warning for PDSS (Postinjection Delirium/Sedation Syndrome) that limits their use.

mdc-CWM

One-time Intraarticular celecoxib to facilitate patient recovery by providing post- operative pain relief for weeks and decreasing the need for addictive opioids

mdc-CWM

In partnership with AIC

Indication

Post-op pain

Molecule

Celecoxib

Status

Clinical Phase 3

Technology

BEPO®

Injected into the intra-articular space during Total Knee Replacement surgery and potentially active for as long as three months post-surgery, mdc-CWM is a sustained-release formulation of celecoxib for the reduction of postoperative pain and inflammation. The mdc-CWM project is a collaboration with Arthritis Innovation Corporation (AIC), based in Toronto, Canada, who finance and conduct the clinical development activities.

Join the team

Unleash your entrepreneurial spirit within a creative and innovative team of international experts dedicated to tackling global health challenges.

June 2024

Corporate presentation

Get in touch

Please use the form for any inquiries. We’ll get back to you promptly.

Nom(Required)
Untitled(Required)